208 related articles for article (PubMed ID: 35779846)
21. Using Osteoporosis Therapies in Combination.
McClung MR
Curr Osteoporos Rep; 2017 Aug; 15(4):343-352. PubMed ID: 28667435
[TBL] [Abstract][Full Text] [Related]
22. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
[TBL] [Abstract][Full Text] [Related]
23. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Leder BZ; Tsai JN; Jiang LA; Lee H
Bone; 2017 May; 98():54-58. PubMed ID: 28286299
[TBL] [Abstract][Full Text] [Related]
24. Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program.
Papaioannou A; Khan A; Belanger A; Bensen W; Kendler D; Theoret F; Amin M; Brekke L; Erdmann M; Walker V; Adachi JD
Curr Med Res Opin; 2015; 31(7):1391-401. PubMed ID: 25993017
[TBL] [Abstract][Full Text] [Related]
25. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
26. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
[TBL] [Abstract][Full Text] [Related]
27. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
28. Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention.
Abrahamsen B; Skjødt MK; Vestergaard P
Bone; 2019 Mar; 120():476-481. PubMed ID: 30583122
[TBL] [Abstract][Full Text] [Related]
29. Antibiotic dispensing during the COVID-19 pandemic: analysis of Welsh primary care dispensing data.
Wasag DR; Cannings-John R; Hughes K; Ahmed H
Fam Pract; 2022 May; 39(3):420-425. PubMed ID: 34755180
[TBL] [Abstract][Full Text] [Related]
30. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
[TBL] [Abstract][Full Text] [Related]
31. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
[TBL] [Abstract][Full Text] [Related]
32. Polypharmacy in Osteoporosis Treatment.
McConnell M; Shieh A
Clin Geriatr Med; 2022 Nov; 38(4):715-726. PubMed ID: 36210087
[TBL] [Abstract][Full Text] [Related]
33. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
[TBL] [Abstract][Full Text] [Related]
34. New therapeutic targets for osteoporosis.
Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
[TBL] [Abstract][Full Text] [Related]
36. The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study.
Park CH; Yoo JI; Choi CH; Suh YS
BMC Musculoskelet Disord; 2020 Nov; 21(1):751. PubMed ID: 33189148
[TBL] [Abstract][Full Text] [Related]
37. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
38. [Anti-osteoporosis drugs : their characteristics and evidence for anti-fracture efficacy].
Takeuchi Y
Clin Calcium; 2012 Jun; 22(6):897-903. PubMed ID: 22653031
[TBL] [Abstract][Full Text] [Related]
39. How the COVID-19 pandemic affected bone health: a retrospective, longitudinal study on denosumab persistence from the epicentre of European spreading.
Varenna M; Orsini F; Di Taranto R; Zucchi F; Manara M; Caporali R; Crotti C
Arch Osteoporos; 2023 Jul; 18(1):95. PubMed ID: 37438617
[TBL] [Abstract][Full Text] [Related]
40. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]